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Abstract
Molecular diagnostics of hereditary breast and/or ovarian cancer is mainly based on detection of BRCA1 and
BRCA2 germline mutations in suspected families. The aim of the study was to determine the frequency, age and
geographical distribution in 130 Slovak hereditary breast and ovarian cancer (HBOC) families diagnosed within
the years 2000-2004. Mutation screening was performed by single-strand conformation polymorphism (SSCP),
heteroduplex analysis (HDA) and sequencing of PCR products showing an abnormal migration pattern. Twenty
of 130 (15.6%) HBOC suspected families were found to carry mutations in BRCA1 or BRCA2 genes. The glossary
data from the National Cancer Registry of Slovakia (NCRS) were compared with the results from HBOC suspected
kindreds. Age distribution of breast cancer onset in our study group showed the highest proportion of onset in
HBC families within the 5th decade of life, while NCRS reports at least a ten year later onset. These findings
confirmed that cases of breast cancer under 50 years of age can be used as one of the principal criteria to
assign a family as a hereditary breast and/or ovarian cancer kindred. In contrast with unselected ovarian cancer
cases, about 75% of all HOC index cases were diagnosed between 40 and 49 years of age. To study the
geographical distribution of hereditary breast and/or ovarian cancer, Slovakia was divided into three parts. The
distribution of HBOC suspected families approximately follows this division, with an increasing number in the
western area of the country.
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Introduction
Breast cancer is the most common malignancy
affecting women in the Slovak Republic, accounting for
1,858 and 1,827 newly diagnosed breast cancer cases
in years 2000 and 2001, respectively (World
Standardized Rates 47.0/100,000 and 46.1/100,000).
The complete data from NCRS show that it is also the
leading cause of cancer-related mortality among Slovak
women, the proportion being 15.1% of all cancer cases.
NCRS was created as one of the first in Central and
Eastern Europe and contains 30-year-old data about
newly diagnosed cancer patients of all types. According
to NCRS evidence, 414 and 449 newly diagnosed
cases of ovarian cancer were reported in years 2000
and 2001 (World Standardized Rates: 10.9/100,000
and 11.4/100,000). They represent 4.3% of all cancer
deaths, and ovarian cancer is therefore the most
frequent cause of death of all gynaecological
malignancies.
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A family history of breast and/or ovarian cancer is
the most significant risk factor for developing the
disease. An estimated 5-10% of all breast and ovarian
cancer cases are hereditary in nature [1]. The search
for genes associated with hereditary susceptibility to
breast or ovarian cancer has been facilitated by the
study of large kindreds with multiple affected
individuals, and has led to the identification of several
susceptibility genes, of which BRCA1 (MIM 113705)
and BRCA2 (MIM 600185) are the most penetrant.
Carriers of germline mutations in these genes have a
50-85% lifetime risk of breast cancer and a 15-45%
risk of developing ovarian cancer during their lifetime
[2, 3]. It was estimated that the combination of
BRCA1/BRCA2 mutations was responsible for
approximately 80% of all HBOC families [4, 5]. More
recent estimates put this risk at about 30% and other
low penetrance candidate genes involved in breast
cancer susceptibility, CHEK2, ATM, TP53 and PTEN,
have been identified [6, 7].
Here we aim to determine the frequency, age and
geographical distribution of families carrying
BRCA1/BRCA2 mutations within our collection of
Slovak HBOC suspected kindreds. For this purpose,
we have performed mutation screening of the entire
coding region of BRCA1 and the first 16 exons of
BRCA2 in 130 Slovak HBOC suspected families.
Knowledge about HBOC families has been compared
with the overall distribution of breast and ovarian
cancer cases in 2001 and 2002, reported by NCRS.
Patients and methods
The collection of Slovak HBOC suspected families
was obtained from the National Cancer Institute, the
Centre of Clinical Genetics of the Faculty Hospital
(Bratislava) and the departments of medical genetics
of hospitals from all over the Slovak Republic. Informed
consent was required prior to testing. Families having
affected women were divided into potentially average,
moderate or high risk of developing breast and/or
ovarian cancer due to their family history. Potentially
average-risk HBOC suspected families were defined
by the presence of one breast cancer diagnosed under
the age of 40, breast and ovarian cancer in the same
individual at any age and bilateral breast cancer.
Moderate risk was defined as two breast or ovarian
cancer cases among first- and second-degree relatives
(index case included) from the same ancestral lineage
or a combination of breast and ovarian cancer among
first-degree relatives. Families with high risk were
characterized by the presence of at least three first- and
second-degree affected relatives (index case included)
on the same lineage of the HBOC suspected proband. 
Mutation screening
Genomic DNA was extracted from peripheral blood
lymphocytes using QIAamp DNA blood kit (Qiagen,
Hilden, Germany). All exons including intron-exon
boundaries of BRCA1 and the first 16 exons of BRCA2
were amplified by PCR using the set of primers
according to Wagner et al. [8]. Mutation screening
methods included SSCP and HDA as previously
described [9]. Fragments showing aberrant band
profiling were sequenced on the ABI PRISM® 3100
Avant Genetic Analyzer (Applied Biosystems, Foster
City, CA, USA). 
Results
The study revealed that 20 of 130 (15.6%) HBOC
suspected families carry mutations in BRCA1/BRCA2
genes using standard molecular techniques that
included SSCP, HDA and subsequent automatic
sequencing of PCR products with aberrant mobility. The
efficiency of BRCA1/BRCA2 mutation detection in
relation to the selection criteria is summarized in Table
1. Most analysed kindreds (80) were classified in the
high-risk group, 40 families belong to the group with
moderate risk and a relatively small number (10) was
at average risk for genetic predisposition. The highest
detection rate (17.5%) of disease-causing BRCA1/2
alleles was identified in the high-risk group of families
with at least 3 breast or ovarian cancer cases. The
majority (85%) of all detected mutations in our
collection were attributable to BRCA1. 
Table 1. The efficiency of mutation detection in relation to selection criteria
Selection Criteria Number of Families BRCA1 mutation (%) BRCA2 mutation (%) Overall mutation (%)
average-risk HBOC 10 1 (10%) - 1 (10%)
moderate-risk HBOC 40 4 (10%) 1 (2.5%) 5 (12.5%)
high-risk HBOC 80 12 (15%) 2 (2.5%) 14 (17.5%)
total 130 17 3 20
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The age distribution of breast and ovarian cancer
onset in the study group is shown in Table 2. Onset of
breast cancer in the HBC group was 9 (8%), 30
(26.5%), 52 (46%), 20 (17.7%) and 2 (1.8%) for age
intervals <29, 30-39, 40-49, 50-59, 60-69,
respectively. The highest proportion of onset was
observed within the 5th decade of life (interval 40-49),
while NCRS reports a ten year later age of disease
Table 2. Age distribution in Slovak HBC and HOC suspected families
Decade HBC families HOC families
overall with mutation overall with mutation
15-29 9 (8%) 1 (9%) 0 (0%) -
30-39 30 (26.5%) 2 (18.2%) 1 (5.9%) -
40-49 52 (46%) 4 (36.4%) 13 (76.5%) 5 (55.5%)
50-59 20 (17.7%) 4 (36.4%) 3 (17.6%) 4 (44.5%)
60-69 2 (1.8%) - - -
total (100%) 113 11 17 9 
Table 3.  Age distribution in unselected breast and ovarian cancer cases according to NCRS* 
Breast Cancer Cases Ovarian Cancer Cases
Decade NCRS* NCRS* 
2000 (%) 2001 (%) 2000 (%) 2001 (%)
15-29 4 (0.2%) 7 (0.4%) 17 (4.1%) 22 (4.9%)
30-39 100 (5.4%) 98 (5.4%) 33 (8%) 17 (3.8%)
40-49 360 (19.4%) 365 (20%) 84 (20.3%) 80 (17.8%)
50-59 444 (23.9%) 449 (24.6%) 84 (20.3%) 102 (22.7%)
60-69 429 (23%) 396 (21.6%) 95 (23%) 96 (21.4%)
70-79 376 (20.2%) 384 (21%) 76 (18.3%) 105 (23.4%)
80+ 145 (7.8%) 128 (7%) 25 (6%) 26 (5.8%)
total (100%) 1858 1827 414 449
* NCRS – National Cancer Register of Slovakia
Table 4. Comparison of geographical distribution between Slovak HBOC suspected families and NCRS registered breast and ovarian cancer
HBOC BRCA1/2 Female Breast Cancer Cases Ovarian Cancer Cases
suspected positive families/ (NCRS*) (NCRS*)
families (%) carriers 2000 (%) 2001 (%) 2000 (%) 2001 (%)
Bratislava 46 (35,4%) 5/8 325 (17.5%) 314 (17.2%) 70 (16.9%) 75 (16.7%)
Western Slovakia 50 (38.5%) 7/29 682 (36.7%) 677 (37%) 142 (34.3%) 171 (38%)
Central and Eastern 
Slovakia 34 (26.1%) 8/14 851 (45.8%) 836 (45.8%) 202 (48.8%) 203 (45.2%)
Total (100%) 130 20/51 1858 1827 414 449
* NCRS – National Cancer Register of Slovakia
onset for sporadic cases (see Table 3). The age
distribution of index cases in 17 ovarian cancer families
were 1 (5.9%), 13 (76.5%) and 3 (17.6%) for intervals
30-39, 40-49, 50-59, respectively. In contrast with the
group of HOC families, where about 3/4 of all cases
were diagnosed again in the 5th decade, more than
half of the unselected ovarian cancer cases developed
disease by the age of 60  years.
To study the geographical distribution of hereditary
breast and/or ovarian cancer we have divided Slovakia
into three parts: 1. Bratislava including the suburban
area, 2. western Slovakia, 3. central and eastern
Slovakia (Table 4). The incidence of HBOC suspected
families approximately follows this geographical
distribution, with a small increase in the western part
of Slovakia. Families with detected BRCA1/2 mutations,
however, are almost equally distributed in all three
regions. 
Discussion
In this report we focused on HBOC, age and
geographical distribution of 130 suspected families
from probands diagnosed with disease between and
including the years 2000 to 2004. To date, no study
addressing the presented features of Slovak HBOC
suspected families with BRCA1/BRCA2 pathogenic
mutations has been reported. Our Department of
Cancer Genetics at the Cancer Research Institute in
Bratislava was the first laboratory to provide molecular
analysis for hereditary breast and/or ovarian cancer
for families, and has state-wide relevance. 
We used the incidence, age and geographical
distribution of unselected breast and/or ovarian cancer
patients from NCRS to compare with the data from the
index cases of HBOC suspected families. NCRS was
established in 1976 and provides a quality database of
incidence and mortality of all cancer types in our country.
To date, 250 members of 130 HBOC families have
been screened for mutations in BRCA1/BRCA2. Of these
130 kindreds, 20 families with pathogenic alterations
have been identified. Identification of 15.6%
BRCA1/BRCA2 positive families correlates with mutation
rates found in other European high-risk populations [10].
In total, 51 mutation carriers from 91 available family
members were detected. Similar to the observations from
mutation screening of women with familial or early onset
breast and/or ovarian cancer in the Czech Republic [11],
the majority (17.5%) of disease-predisposing
BRCA1/BRCA2 alleles were identified in a group of high-
risk HBOC families (Table 1).
The relative contribution of BRCA1 and BRCA2
appeared to be unequal and most of the pathogenic
mutations were found in the BRCA1 gene (see Table
1). It has to be noted that our screening strategy
including the first 16 exons of BRCA2 and the
remaining exons of the gene needs to be analysed.
Although the experimental approach used (a
combination of SSCP, HDA and DNA sequencing) has
a very high detection rate, some loss-of-function
mutations and all large genomic rearrangements were
not capable of being detected using this strategy. Such
rearrangements are believed to be responsible for 10%
to 15% of BRCA1 inactivating mutations [12]. 
Our findings confirmed that early age of breast and
ovarian cancer onset (before the age of 50) is one of
the best criteria for assigning the family as hereditary
breast and/or ovarian cancer kindreds (Table 2).
According to improvements in the overall education
and prompt application of results from BRCA1/BRCA2
mutation screening, one can predict that the
identification of women at risk of disease will shift to
an earlier age and also to a lower stage of disease by
virtue of active prophylactic screening measures. 
When we look at the distribution of HBOC
suspected families within the three regions of Slovakia,
differences in the frequencies of families in particular
areas can be seen. This is most likely caused by
historical, industrial and information-level distinctions
between the different geographical regions that are
manifested as different frequencies of kindreds with
proven mutations in BRCA1/BRCA2. The largest
difference is primarily between western (which includes
the capital, Bratislava) and eastern parts of the country.
The change in HBOC frequency can be explained by
the decreasing number of hospitals with departments
of clinical genetics from the western to the eastern
territories of the Slovak Republic. That therefore best
explains  the number of HBOC suspected families from
these regions that did not appear to correlate with the
overall distribution of unselected breast and ovarian
cancer cases reported by NCRS. 
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